These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 27725068)

  • 21. Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.
    Cereda V; Formica V; Massimiani G; Tosetto L; Roselli M
    Expert Opin Investig Drugs; 2014 Apr; 23(4):469-87. PubMed ID: 24490883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug therapies for metastatic castration-resistant prostate cancer.
    El-Bahesh E; Finianos A; Alfaraj A; Aragon-Ching JB
    Future Oncol; 2015; 11(17):2395-403. PubMed ID: 26274603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.
    Azad AA; Leibowitz-Amit R; Eigl BJ; Lester R; Wells JC; Murray RN; Kollmannsberger C; Heng DY; Joshua AM; Chi KN
    Prostate; 2014 Nov; 74(15):1544-50. PubMed ID: 25175831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
    Azad AA; Volik SV; Wyatt AW; Haegert A; Le Bihan S; Bell RH; Anderson SA; McConeghy B; Shukin R; Bazov J; Youngren J; Paris P; Thomas G; Small EJ; Wang Y; Gleave ME; Collins CC; Chi KN
    Clin Cancer Res; 2015 May; 21(10):2315-24. PubMed ID: 25712683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Metastatic castration-resistant prostate cancer : Clinical data, new treatment options and therapy monitoring].
    Miller K; Albers P; Eichenauer R; Geiges G; Grimm MO; König F; Mickisch G; Pfister D; Schwentner C; Suttmann H; Zastrow S
    Urologe A; 2016 Sep; 55(9):1206-12. PubMed ID: 27411995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enzalutamide Prior to Radium-223 Is Associated with Better Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Compared to Abiraterone-A Retrospective Study.
    Chen HX; Tsai LH; Chang CH; Wu HC; Lin CC; Lin CH; Yeh CC; Yang CR; Lien CS; Chang YH; Liang JA; Chen GH; Hsiao PJ; Hsieh PF; Huang CP
    Cancers (Basel); 2023 Jul; 15(13):. PubMed ID: 37444626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integrating radium-223 therapy into the management of metastatic prostate cancer care: a plain language summary.
    O'Sullivan JM; Abramowitz E; Sierra-Scacalossi L
    Future Oncol; 2023 May; 19(15):1021-1028. PubMed ID: 36942803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current therapeutic options in metastatic castration-resistant prostate cancer.
    Ingrosso G; Detti B; Scartoni D; Lancia A; Giacomelli I; Baki M; Carta G; Livi L; Santoni R
    Semin Oncol; 2018 Oct; 45(5-6):303-315. PubMed ID: 30446166
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme.
    Maines F; Caffo O; De Giorgi U; Fratino L; Lo Re G; Zagonel V; D'Angelo A; Donini M; Verderame F; Ratta R; Procopio G; Campadelli E; Massari F; Gasparro D; Ermacora P; Messina C; Giordano M; Alesini D; Basso U; Fraccon AP; Vicario G; Conteduca V; Galligioni E
    Clin Genitourin Cancer; 2016 Feb; 14(1):48-55. PubMed ID: 26382222
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Value of treatment in clinical trials versus the real world: the case of abiraterone acetate (Zytiga) for postchemotherapy metastatic castration-resistant prostate cancer patients in Sweden.
    Svensson J; Andersson E; Persson U; Edekling T; Ovanfors A; Ahlgren G
    Scand J Urol; 2016 Aug; 50(4):286-91. PubMed ID: 27109827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
    Li J; Armstrong AJ
    Clin Adv Hematol Oncol; 2015 May; 13(5):293-8. PubMed ID: 26352773
    [No Abstract]   [Full Text] [Related]  

  • 32. Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science.
    Nussbaum N; George DJ; Abernethy AP; Dolan CM; Oestreicher N; Flanders S; Dorff TB
    Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):111-21. PubMed ID: 26832363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of bone-targeted therapies for prostate cancer in 2017.
    Traboulsi SL; Saad F
    Curr Opin Support Palliat Care; 2017 Sep; 11(3):216-224. PubMed ID: 28644302
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal usage of radium-223 in metastatic castration-resistant prostate cancer.
    Cha TL; Wu TT; Vogelzang NJ; Huang CY; Huang SP; Lin CC; Ou YC; Pang ST; Shen DH; Wu WJ; Chang WY
    J Formos Med Assoc; 2017 Nov; 116(11):825-836. PubMed ID: 29046247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer.
    Han CS; Patel R; Kim IY
    Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):967-75. PubMed ID: 25936418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
    Pond GR; Armstrong AJ; Galsky MD; Wood BA; Leopold L; Sonpavde G
    Urol Oncol; 2013 Nov; 31(8):1457-63. PubMed ID: 22552048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics.
    Mukherji D; Omlin A; Pezaro C; Shamseddine A; de Bono J
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):555-66. PubMed ID: 24452758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker.
    Heinrich D; Bruland Ø; Guise TA; Suzuki H; Sartor O
    Future Oncol; 2018 Oct; 14(24):2543-2556. PubMed ID: 29925281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence.
    Norum J; Nieder C
    Pharmacoeconomics; 2017 Dec; 35(12):1223-1236. PubMed ID: 28756597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Navigating Treatment of Metastatic Castration- Resistant Prostate Cancer: Nursing Perspectives.
    dela Rama F; Pratz C
    Clin J Oncol Nurs; 2015 Dec; 19(6):723-32. PubMed ID: 26583636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.